23ME610 by 23AndMe Holding for Merkel Cell Carcinoma: Likelihood of Approval

23ME610 is under clinical development by 23andMe Holding and currently in Phase II for Merkel Cell Carcinoma.

Exercise boosts tumor-killing white blood cells in breast cancer patients

A new Finnish study from University of Turku shows that already a 30-minute exercise can increase the proportion of tumor-killing white blood cells in the

July 3, 2024

Prevention over cure? Understanding the evolved care continuum and centralised data – Pharmaceutical Technology

Share this article You’ve heard the phrase “prevention is better than the cure”. It’s generally attributed to the Dutch philosopher Desiderius Erasmus in around 1500.

March 19, 2024

StitchR technology delivers large genes for muscular dystrophy treatment

Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is a big problem: size.

November 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.